193 related articles for article (PubMed ID: 21281874)
1. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children.
Kuna P; Kaczmarek J; Kupczyk M
J Allergy Clin Immunol; 2011 Feb; 127(2):502-508.e1-6. PubMed ID: 21281874
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety.
Tabar AI; Lizaso MT; García BE; Gómez B; Echechipía S; Aldunate MT; Madariaga B; Martínez A
Pediatr Allergy Immunol; 2008 Feb; 19(1):67-75. PubMed ID: 17651380
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial.
Pozzan M; Milani M
Curr Med Res Opin; 2010 Dec; 26(12):2801-6. PubMed ID: 21050060
[TBL] [Abstract][Full Text] [Related]
4. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma.
Tabar AI; Lizaso MT; García BE; Echechipía S; Olaguibel JM; Rodríguez A
J Investig Allergol Clin Immunol; 2000; 10(6):327-33. PubMed ID: 11206932
[TBL] [Abstract][Full Text] [Related]
5. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
6. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
Caramia G; Franceschini F; Cimarelli ZA; Ciucchi MS; Gagliardini R; Ruffini E
Allerg Immunol (Paris); 1996 Nov; 28(9):308-10. PubMed ID: 8986246
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of mold allergy: A review.
Bozek A; Pyrkosz K
Hum Vaccin Immunother; 2017 Oct; 13(10):2397-2401. PubMed ID: 28481693
[TBL] [Abstract][Full Text] [Related]
8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of alternaria alternata allergy: a prospective study in 6840 Italian asthmatic children.
Cantani A; Ciaschi V
Eur Rev Med Pharmacol Sci; 2004; 8(6):289-94. PubMed ID: 15745389
[TBL] [Abstract][Full Text] [Related]
10. Alternaria allergy: a three-year controlled study in children treated with immunotherapy.
Cantani A; Businco E; Maglio A
Allergol Immunopathol (Madr); 1988; 16(1):1-4. PubMed ID: 3381709
[TBL] [Abstract][Full Text] [Related]
11. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
Ibáñez Sendín MD
Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
[TBL] [Abstract][Full Text] [Related]
13. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
14. [Vaccination against allergies yields good symptom relief].
Hedlin G; Arvidsson M
Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1938-41. PubMed ID: 18681376
[No Abstract] [Full Text] [Related]
15. Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters.
Lizaso MT; Tabar AI; García BE; Gómez B; Algorta J; Asturias JA; Martínez A
Pediatr Allergy Immunol; 2008 Feb; 19(1):76-81. PubMed ID: 17662037
[TBL] [Abstract][Full Text] [Related]
16. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
17. Clinical evolution of patients with respiratory allergic disease due to sensitisation to Alternaria alternata being treated with subcutaneous immunotherapy.
Zapatero L; Martínez-Cañavate A; Lucas JM; Guallar I; Torres J; Guardia P; Torre Fde L; Pedemonte C
Allergol Immunopathol (Madr); 2011; 39(2):79-84. PubMed ID: 21236554
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases.
Malling HJ; Bousquet J
Clin Allergy Immunol; 2008; 21():343-58. PubMed ID: 18828516
[No Abstract] [Full Text] [Related]
20. Biological standardization and maximum tolerated dose estimation of an Alternaria alternata allergenic extract.
Lizaso MT; Martínez A; Asturias JA; Algorta J; Madariaga B; Labarta N; Tabar AI
J Investig Allergol Clin Immunol; 2006; 16(2):94-103. PubMed ID: 16689182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
